<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2553">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298060</url>
  </required_header>
  <id_info>
    <org_study_id>DAS181-2-07</org_study_id>
    <nct_id>NCT04298060</nct_id>
  </id_info>
  <brief_title>DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)</brief_title>
  <acronym>STOP-Flu</acronym>
  <official_title>A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ansun Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ansun Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and
      pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be
      enrolled into this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohort 1: It is designed as a two stage, multi-center, randomized, double-blind, two parallel
      doses, placebo-controlled study that will investigate the efficacy of DAS181 for the
      treatment of serious IFV in hospitalized patients who suffered from acute hypoxemia requiring
      supplemental oxygen therapy.

      Cohort 2: It is designed as an open-label study that will investigate the efficacy of DAS181
      for the treatment of patients with sever IFV but not eligible for Cohort 1 and non-IFV SAD
      viral infection, e.g. parainfluenza virus, human metapneumovirus, enterovirus and all strains
      of β-coronaviruses (including but not limited to SARS-CoV-2), with hypoxemia requiring
      supplemental oxygen therapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Stage 2, Ansun will know the dosage.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects who have returned to room air</measure>
    <time_frame>7 days</time_frame>
    <description>Percent of subjects who have returned to room air</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change of subjects return to baseline oxygen requirement</measure>
    <time_frame>7 days</time_frame>
    <description>Percent change of subjects return to baseline oxygen requirement by Day 7 compared to Day 1</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Influenza Infection</condition>
  <condition>SAD-RV Infection and COVID-19</condition>
  <arm_group>
    <arm_group_label>DAS181 SD group Cohort 1, Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAS181 SD group 4.5mg/day for 7 or 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAS181 HD group Cohort 1, Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAS181 HD group 9mg/day for 7 or 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Cohort 1, Stage 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0mg/day for 7 or 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAS181 group, Cohort 1, Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Cohort 1, Stage 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0mg/day for 7 or 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAS181 group, Cohort 2, Stage1 and 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAS181 4.5mg/day or 9mg/day for 7 or 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAS181</intervention_name>
    <description>SD (4.5mg/day), HD (9mg/day)</description>
    <arm_group_label>DAS181 HD group Cohort 1, Stage 1</arm_group_label>
    <arm_group_label>DAS181 SD group Cohort 1, Stage 1</arm_group_label>
    <arm_group_label>DAS181 group, Cohort 1, Stage 2</arm_group_label>
    <arm_group_label>DAS181 group, Cohort 2, Stage1 and 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 0mg/day</description>
    <arm_group_label>Placebo, Cohort 1, Stage 1</arm_group_label>
    <arm_group_label>Placebo, Cohort 1, Stage 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria of Cohort 1 #4 is adapted from the Flu guideline in China (2018) and
        community acquired pneumonia (CAP) guideline in China (2016)

        Cohort 1:

        Subjects must meet all of the following inclusion criteria at the time of randomization to
        be eligible for participation in this study:

          1. Males and Females ≥18 years old

          2. Diagnosed as influenza (IFV) infection within 3 days before randomization

          3. Requires, at the time of randomization, supplemental oxygen ≥2 LPM due to hypoxemia

          4. Subjects are severely ill

          5. In the opinion of investigator, subjects will be hospitalized at least 1 week.

          6. If female, subject must not be pregnant or nursing

        Cohort 2:

        Subjects must meet all of the following inclusion criteria at the time of randomization to
        be eligible for participation in this study:

          1. Males and Females ≥18 years old

          2. Hypoxemia

          3. Subjects fulfill one of the following conditions:

               1. IFV subjects who are eligible for all inclusion criteria of Cohort 1 except for
                  acute hypoxemia at enrollment.

               2. Subjects confirmed with non-IFV SAD viral infection.

          4. Same in inclusion criteria #5 to #8 in Cohort 1.

        Exclusion Criteria

        Cohort 1 and 2:

        Subjects who meet any of the following exclusion criteria are not to be enrolled in this
        study:

          1. Subjects requiring mechanical, Bi-PAP or CPAP ventilation at randomization.

          2. Life expectancy less than 30 days.

          3. Subjects with conscious disturbance (slow response, drowsy, restlessness, anxiety,
             confusion, twitching or convulsion)

          4. Subjects with unstable hemodynamics such as systolic blood pressure &lt; 90 mmHg or
             septic shock

          5. Subjects with BUN≧7.14 mmol/L

          6. Subjects treated with inhaled anti-viral therapy and washout period ≦ 48 hours.

          7. If Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) or Alkaline
             Phosphatase (ALP) are ≥3x ULN and Total Bilirubin (TB) is ≥2x ULN.

          8. Female subjects with positive pregnancy test result, breastfeeding or planning to
             breastfeed at any time through 30 days after the last dose of study drug.

          9. Subjects taking any other investigational drug used to treat for another respiratory
             infection.

         10. Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion
             of the principal investigator, would affect subject safety and/or compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Ho, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ansun Biopharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivy Fan</last_name>
    <phone>+86 186 2190 9313</phone>
    <email>ifan@ansunbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvie Lu-Hinh</last_name>
    <phone>858-452-2631</phone>
    <phone_ext>199</phone_ext>
    <email>slu-hinh@ansunbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe hospitalized influenza</keyword>
  <keyword>Lower Respiratory Tract Disease</keyword>
  <keyword>Acute Hypoxemia</keyword>
  <keyword>DAS181</keyword>
  <keyword>Ansun</keyword>
  <keyword>infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

